AM-Pharma announces loan of up to €5 million from Dutch Government

Dutch Government supports AM-Pharma in development of first drug against Acute Kidney Injury Bunnik, The Netherlands, March 19, 2009. AM-Pharma B.V., the biopharmaceutical company developing endogenous proteins to combat disease, today announced it is receiving a loan of up to €5 million from SenterNovem, an agency of the Dutch Ministry of Economic affairs. The loan […]

AM-Pharma announces start of second Phase II trial in Acute Renal Failure

Bunnik, The Netherlands, 9 July 2008. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins and peptides against inflammatory and infectious disease, today announced the start of a second Phase II trial of bovine derived Alkaline Phosphatase to treat Acute Renal Failure. The trial will be double blind placebo controlled and will include 26 patients. […]

AM-Pharma announces €7 million First Close of series C financing round

Existing investors support AM-Pharma and set the terms for Second Close Bunnik, The Netherlands, 28 May 2008. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins and peptides to combat disease, today announced the signing of a €7 million financing agreement with Forbion Capital Partners and Inventages Venture Capital. The announced investment is a First […]

AM-Pharma announces appointment of new VP Clinical Development

Bunnik, The Netherlands, 18 February 2008. AM-Pharma B.V., the biopharmaceutical company developing optimised endogenous proteins and peptides to combat disease, today announced the appointment of Jacques Arend as Jacques Arend, MD joined the pharmaceutical industry in 1988, in medical and clinical development positions. He started at SmithKline Beecham, and then became international coordinator clinical development […]

AM-Pharma announces appointment of Chief Business Officer

Bunnik, The Netherlands, 17 September 2007. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins to combat disease, today announced the appointment of Erik van den Berg as Chief Business Officer. Erik van den Berg MSc MBA, joins from Organon, where he was leading the global biotech business development efforts. Prior to joining Organon, he […]

AM-Pharma announces €2.5 million financing

Bunnik, The Netherlands, 3 August 2007. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins to combat disease, today announced the signing of a €2.5 million financing agreement with its two main investors, Forbion Capital Partners and Inventages Venture Capital. The investment is a prelude to a Series C financing round, for which AM-Pharma is […]

AM-Pharma announces positive results of Phase IIa clinical trial with Alkaline Phosphatase for ulcerative colitis

Bunnik, The Netherlands, 9 July 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced the positive clinical results of its Phase IIa Alkaline Phosphatase (AP) trial for patients with ulcerative colitis, a chronic and relapsing inflammatory bowel disease affecting the colon. In this recent trial, AP was […]

AM-Pharma announces positive results of a Phase IIa clinical trial with Alkaline Phosphatase in Acute Kidney Injury

Bunnik, The Netherlands, 12 March, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced positive results in patients with Acute Renal Failure. The patients involved were a subgroup of a Phase IIa trial with Alkaline Phosphatase to treat Sepsis. Plasma creatinine clearance, a marker for renal function, […]

AM-Pharma announces the appointment of Bart Wuurman as CEO

Bart Wuurman, M. Sc. replaces Bruno Giannetti, MD., Ph.D., who left AM-Pharma in December 2006. Bart Wuurman has 18 years of International Pharma and Biotechnology Industry experience with Organon, Medeva and Antisoma, where he was responsible for a $500 million oncology alliance with Roche. In 2003 Bart became CEO of De Novo Pharmaceuticals in Cambridge, […]

Dutch Biopharmaceutical Company AM-Pharma announces positive results in its double-blind, placebo controlled Phase IIa Sepsis trial with Alkaline Phosphatase

Bunnik, the Netherlands, 20 October 2006. AM-Pharma B.V., a biopharmaceutical company engaged in the pre-clinical and early clinical development of novel compounds to treat infectious and inflammatory diseases, announces first positive results observed in its multi-center double blind, placebo-controlled pilot study in the treatment of sepsis with its patented Alkaline Phosphatase (AP) drug. The study […]